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Background: Micronutrient laboratory tests (MLT) are increasing in many healthcare 
systems. This study assessed time trends of annual MLT incidence in the Swiss population 
and examined the frequency of specific MLT, defined as the number of yearly tests 
performed in individual persons.
Methods: For annual time trends, we used a longitudinal design with a seven-year observa-
tion period (2012–2018) and for yearly testing frequency we used a cross-sectional design 
(2018 only). The database consisted of nationwide insurance claims from adult persons.
Results: Persons with MLT compared to persons without were older (mean age 57.1 years vs 
48.6 years) and to a higher proportion female (65.1% vs 45.5%). Between 2012 and 2018, we 
included 6.7 million person years and found an increase in the proportion of persons 
receiving any MLT from 24.5% to 35.0%. Tests with strongest absolute increase during 
the observation period were vitamin D (from 7.4% of persons to 20.4%), vitamin B12 (from 
9.0% to 17.6%) and ferritin (from 17.4% to 26.6%). In 2018, vitamin D and vitamin B12 
tests were performed more than once in 4.5% and 3.3% of the population, respectively.
Conclusion: We found that the Swiss population undergoes MLT with high and increasing 
frequency. Testing for vitamin D, vitamin B12 and ferritin is very common and of question-
able appropriateness.
Keywords: laboratory testing, micronutrient, claims data, trend
Introduction
Laboratory testing plays a key role in the treatment of patients and is essential for 
clinical decision-making. A high proportion of physicians’ decisions rely on 
laboratory testing results in clinical practice.1 However, in the last decades, labora-
tory testing significantly increased in nearly all industrialized countries; as data 
from several countries such as Canada, UK, and Sweden reflect. Questions have 
been raised on whether all these tests were appropriate and had consequences for 
clinical decision-making.2–4 While increases in specific laboratory tests can be 
understood before the background of demographic changes, an increase in micro-
nutrient laboratory testing (MLT) is difficult to understand especially in developed 
countries. However, studies on a comprehensive set of micronutrient tests are very 
scarce and only a few studies focusing on a specific micronutrient test such as 
vitamin D exist.3–6 For example, increased testing for vitamin D has been observed 
in several countries, and even though guidelines do not advocate or even discourage 
screening for vitamin D deficiency.5–10
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In Switzerland, a recent database analysis found 
increasing MLT use in general practice but comprehensive 
population-based studies are still lacking.11 Such insights, 
however, are necessary to advance the understanding of 
potential overuse of MLT. Therefore, the aim of this study, 
was to assess population-based time trends, incidence and 
frequency of MLT in Switzerland.
Methods
Design and Setting
We performed a retrospective population-based study incor-
porating both a longitudinal and a cross-sectional design 
using electronic healthcare claims database from one of the 
largest health insurance companies in Switzerland (Helsana 
Group). The database contained nationwide data, including 
pharmacy, medical and health services records, from about 
1.2 million mandatorily insured persons across all cantons 
(~15% of the Swiss population). We considered all health-
care invoices submitted to Helsana Group for reimburse-
ment and extracted, deidentified and anonymized persons’ 
data from the Helsana data warehouse for analysis. As 
already shown in previous analysis, Helsana claims data 
are a representative sample from the Swiss general 
population.12,13 Every Swiss resident is obligated to be 
enrolled in a basic health insurance, which is provided by 
health insurers on private market, but regulated by federal 
authorities. The basic health insurance is obligated to offer 
basic health insurance to every Swiss resident and to guar-
antee medical treatment. We included anonymized claims 
data records from 2012 to 2018 containing information on 
sociodemographic characteristics and laboratory testing of 
mandatorily insured persons ≥18 years of age. For the long-
itudinal design, we analyzed claims data per person 
and year (2012–2018), and for the cross-sectional design, 
we included claims data per person in the most recent year, 
2018. The analyzed data of this study are available from the 
Helsana Group but restrictions exist for the availability of 
these data that were used under license for the current study. 
Data are therefore not publicly accessible but can be 
obtained from the authors by reasoned request and with 
permission from Helsana.
Laboratory Tests
A sample of MLT was selected from the list of analyses 
(AL) from the Federal Office of Public Health.14 The AL 
contains all laboratory tests covered by the mandatory 
health insurance in Switzerland. The selected laboratory 
tests were categorized into a vitamin domain (including 
vitamin D, folic acid, homocysteine, methylmalonic acid, 
holotranscobalamin, vitamin B12/cyanocobalamin, and 
other vitamins), a mineral domain (including magnesium 
and calcium) and a trace elements domain (including iron, 
ferritin, transferrin, and other trace elements). A detailed 
list of included MLT and categories is shown in 
Supplementary Table S1. Tests were aggregated when 
they measured closely related metabolites (eg different 
forms of vitamin D).
Objectives
To determine trends in MLT by measuring absolute annual 
changes in proportions of persons receiving any or specific 
MLT during the total observation period (longitudinal design).
To determine incidence of specific MLT stratified by 
age groups.
To determine frequency of MLT by counting the num-
ber of MLTs ordered in individual persons in 2018 (cross- 
sectional design).
Statistical Analysis
Using data from 2012 to 2018 (longitudinal), we assessed 
trends in MLT over seven years by calculating the inci-
dence of laboratory testing per year as the proportions of 
persons receiving MLT (any, by domain and by individual 
test) in the total sample. Multiple tests of the same MLT 
were thereby considered as one test in this analysis. To 
calculate the absolute annual changes in testing for MLT 
over the years (2012–2018), a linear regression model was 
computed using year as continuous variable. Estimates 
were reported as coefficients including 95% confidence 
intervals (95%-CI). Statistical significance was set at the 
0.05 level. In addition, we report relative changes over the 
total seven-year observation period, which were calculated 
by dividing the proportion of persons with the given test in 
2012 by those with the test in 2018.
To calculate incidence by age groups we used the data 
from 2018 exclusively (cross-sectional) and stratified the 
population in those aged 18–44, 45–64 and ≥65.
To assess frequency of MLT in individual persons we 
also used data from 2018, counted the number of individual 
tests per person and reported proportions of persons receiv-
ing no test, one test, two tests, or more than two tests.
We report data using descriptive statistics and use group 
comparison tests. Categorical variables were presented as 
absolute numbers of persons and percentages, continuous 
data as mean value including standard deviation. The 
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Pearson’s chi-squared test was used to test categorical vari-
ables for independency. Differences regarding to continuous 
variables such as age (in years) were analyzed with 
a nonparametric analysis of variance (Kruskal–Wallis test 
for >2-groups-comparisons). Statistical significance was set 
at the 0.05 level. All analyses were performed using the 
statistical program R version 3.6.1 (R Development Core 
Team 2019).
Results
Trends in MLT (Longitudinal)
During the seven-year observation period, we included 
6.7 million person years. Population sizes by year ranged 
between 906,230 (in 2017) and 997,761 (in 2012). In 2012, 
the proportion of persons receiving any MLT was 24.5% and 
the absolute annual change was +1.8% (95% CI = 1.5% to 
2.1%; relative seven-year increase by a factor of 1.4). We 
observed annual increases of proportions of persons receiv-
ing any MLT across all MLT domains, the strongest increase 
appeared in vitamin testing with +2.2% (95% CI = +2.0% to 
+2.4%; relative seven-year increase by a factor of 2.0). For 
trends in overall and domain specific MLT see Table 1.
We found statistically significant annual increases 
in percent of the population tested in every individual 
MLT (Table 2). The largest annual increases we found in 
proportions of persons tested for vitamin D (+2.2%; 95% CI 
= 2.0% to 2.5%), vitamin B12 (+1.5%; 95% CI = 1.4% to 
1.6%) and ferritin (+1.5%; 95% CI = 1.4% to 1.7%). Figures 
1 and 2 show trends in MLT on the level of individual tests.
Sociodemographic Characteristics 
(Cross-Sectional)
From the year 2018, we included 934,685 adult persons, 
52.4% women with mean age 51.5 years (SD 19.7; results 
not shown). Overall, about 35% of the persons had at least 
one MLT in 2018. Considerable differences appeared 
when comparing persons receiving micronutrient testing 
with those who did not: Patients with MLT were older 
(mean age 57.1 years vs 48.6 years), and to a higher 
proportion of female gender (65.1% vs 45.5%; Table 3). 
Differences in language regions were small.
Concerning MLT by age groups, we found that persons 
≥65 years old had the highest testing incidence consis-
tently across all specific MLT. The highest incidence in 
this group we noted in testing for ferritin (34.1%), vitamin 
D (29.7%) and vitamin B12 (26.8%). Conversely, persons 
18–44 years old had the lowest testing incidences, but the 
ranks in the distribution were similarly distributed with 
ferritin in first place (22.0%), vitamin D second (13.2%) 
and vitamin B12 third (11.3%). Table 4 shows testing 
incidences in 2018 by age groups.
Frequency of MLT
Our data comprised 1.29 million MLT in 2018. Most 
frequently ordered MLT were ferritin (0.30 million), vita-
min D (0.21 million) and vitamin B12 (0.18 million). In 
terms of testing frequency, ferritin was in first place being 
performed in 26.6% of persons (19.4% performed once; 
7.3% performed twice or more) followed by vitamin 
Table 1 Proportions of Persons with MLT by Years 2012–2018
Variables Year Absolute Annual 
Change [95%-CI]
2012 2013 2014 2015 2016 2017 2018
N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Total 997,761 
(100.0%)
988,564 
(100.0%)
978,171 
(100.0%)
981,735 
(100.0%)
956,119 
(100.0%)
906,230 
(100.0%)
934,685 
(100.0%)
Persons with ≥1 test 
for MLT
244,926 
(24.5%)
265,719 
(26.9%)
284,553 
(29.1%)
300,770 
(30.6%)
313,897 
(32.8%)
311,166 
(34.3%)
327,320 
(35.0%)
1.8% (1.5–2.1%)
Persons with ≥1 
vitamin test
134,931 
(13.5%)
158,715 
(16.1%)
180,220 
(18.4%)
201,539 
(20.5%)
221,974 
(23.2%)
228,942 
(25.3%)
246,820 
(26.4%)
2.2% (2.0–2.4%)
Persons with ≥1 
mineral test
109,005 
(10.9%)
118,731 
(12.0%)
129,601 
(13.2%)
137,743 
(14.0%)
145,410 
(15.2%)
145,420 
(16.0%)
153,393 
(16.4%)
1.0% (1.0–1.0%)
Persons with ≥1 trace 
element test
179,403 
(18.0%)
195,912 
(19.8%)
211,491 
(21.6%)
226,085 
(23.0%)
236,407 
(24.7%)
235,578 
(26.0%)
251,372 
(26.9%)
1.5% (1.3–1.7%)
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D 20.4% (15.9% performed once; 4.5% performed twice 
or more) and vitamin B12 17.6 (14.3% performed once; 
3.3% performed twice or more). Table 5 shows more detail 
about the number MLT by individual test.
Discussion
In this study, we explored population wide trends in MLT 
in Switzerland during 2012 to 2018. We found an increase 
in all individual MLT but especially so in testing for 
vitamins where the proportion of tested persons doubled 
within seven years. Most eminently, the population tested 
for vitamin D tripled and the population tested for vitamin 
B12 doubled. The population tested for ferritin only 
increased by a factor of 1.5 but ferritin was the most 
prevalent test, ordered at least once in every fourth person 
in 2018. In addition, we explored incidence of MLT and 
frequency in 2018 and found that testing was also very 
common in the young population and that ferritin, vitamin 
D and vitamin B12 were performed more than once in 
over 7%, 4% and 3% of the population. Our results show 
that MLT are performed in a broad segment of the Swiss 
population and with high frequency in large number of 
cases.
We found that MLT are performed in an annually increas-
ing proportion of the adult Swiss population: while a quarter 
of the population received any MLT in 2012, in 2018 already 
a third received an MLT. Among the individual MLT we 
observed strongest absolute increases in testing for vitamin 
D, vitamin B12 and ferritin: Vitamin D testing was per-
formed in 7% of the population in 2012 and in 20% in 
Table 2 Temporal Changes of MLT
Variables Absolute Annual Change (95%-CI) Proportion of Persons Tested in 2012 Relative Seven-Year Change
Vitamin D +2.2% (2.0–2.5%) 7.40% 2.8
Vitamin B12 +1.5% (1.4–1.6%) 9.00% 2.0
Ferritin +1.5% (1.4–1.7%) 17.40% 1.5
Folic acid +1.0% (1.0–1.1%) 5.40% 2.1
Holotranscobalamin +0.9% (0.8–0.0.9%) 2.90% 2.8
Calcium +0.9% (0.8–0.9%) 10.50% 1.5
Magnesium +0.3% (0.3–0.4%) 2.20% 1.9
Iron +0.3% (0.3–0.4%) 4.00% 1.5
Transferrin +0.3% (0.3–0.3%) 1.70% 2.1
Other trace elements +0.2% (0.2–0.2%) 0.70% 2.4
Homocysteine +0.1% (0.1–0.1%) 0.40% 1.7
Other vitamins +0.1% (0.1–0.1%) 0.50% 2.4
Methylmalonic acid +0.0% (−0.01–0.03%) 0.01% 10.0
Figure 1 Temporal use of vitamin tests (2012–2018). Figure 2 Temporal use of mineral and trace elements tests (2012–2018).
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2018 and was thereby both frequently performed and subject 
to a large absolute and relative increase. Regarding testing for 
vitamin B12, we also found both a high testing frequency and 
in addition a strong temporal increase. Moreover, ferritin was 
also among the MLT that were frequently performed and 
increasing over time. Together, tests of vitamin D, vitamin 
B12 and ferritin represent more than half of the MLTs per-
formed but it is noteworthy that significant temporal 
increases occurred also in every other observed MLT without 
exception. Several studies so far found that laboratory testing 
is generally increasing and especially so for vitamin labora-
tory test.2–4,11 While this obviously reflects a global phenom-
enon also occurring in Switzerland, the observation remains 
still largely unexplained and paradox since we are unaware 
of a nutritional deficiency crisis in Switzerland, as in all the 
other countries where this trend has been observed. To find 
the highest incidence among MLT for ferritin testing is con-
sistent with iron deficiency being the most common nutri-
tional disorder also in industrialized countries.15,16 However, 
population based screening for iron deficiency is not recom-
mended by eminent international guidelines such as the US 
Preventive Services Task Force (USPSTF), not even in the 
subgroup of pregnant women.17 Similarly, in the general 
population, screening for vitamin D deficiency is discour-
aged by the USPSTF and recommendations for screening for 
vitamin B12 deficiency are lacking entirely.10 In contrast, we 
found that in 2018 at least 27%, 20% and 18% of the entire 
Swiss population received at least one ferritin, vitamin D or 
vitamin B12 respectively. Such a high testing coverage 
resembles a de-facto population based screening which is 
not supported also by local guidelines and can be criticized at 
least for low value care or even overtesting. While our data 
was insufficient to advance the understanding of reasons for 
the high testing incidence or appropriateness in individual 
cases, several recent studies suggests that rates of inappropri-
ate laboratory testing has increased considerably especially 
involving MLT.2,5,18–20 One possible explanation for the high 
testing rates could be that physicians have financial incen-
tives for testing in the Swiss healthcare system, which may 
influence the testing rates.21
The finding that the population ≥65 has the highest 
testing incidence is consistent with expectations since it 
represents the population segment at highest risk for 
micronutrient deficiencies.22,23 There is little external 
reference available for contrasting these results but 
a recent study of vitamin D testing incidence in the UK 
found that vitamin D testing incidence was 1.6% in 2015 
which was already questioned of appropriateness.24 Our 
results of a testing incidence for vitamin D of 20% is more 
than ten times higher than that therefore even more ques-
tionable for appropriateness, especially in persons 18–44 
years old.
Table 3 Sociodemographic Characteristics of the Study Sample 
from 2018
Variables With MLT Without MLT P-value
N (%) N (%)
Total 327 320 (100.0%) 607 365 (100.0%)
Gender <0.001
Female 213 200 (65.1%) 276 425 (45.5%)
Male 114 120 (34.9%) 330 940 (54.5%)
Mean age (±SD) 57.1 (19.5) 48.6 (19.1) <0.001
Age in groups (years) <0.001
18–24 20,313 (6.2%) 71,409 (11.8%)
25–34 34,057 (10.4%) 100,268 (16.5%)
35–44 40,516 (12.4%) 103,896 (17.1%)
45–54 48,269 (14.7%) 105,467 (17.4%)
55–64 52,072 (15.9%) 90,202 (14.9%)
65–74 57,891 (17.7%) 67,124 (11.1%)
75–84 50,645 (15.5%) 43,855 (7.2%)
≥85 23,557 (7.2%) 25,144 (4.1%)
Language region <0.001
German 232 671 (71.1%) 463,127 (76.3%)
French 66,217 (20.2%) 110,063 (18.1%)
Italian 28,432 (8.7%) 34,175 (5.6%)
Table 4 Incidence of MLT by Age Group in 2018
Tests Age Group (years)
18–44 45–64 ≥65
N (%) N (%) N (%)
Vitamins (all) 63,341 (17.1%) 77,380 (26.1%) 106,099 (39.6%)
Vitamin D 48,887 (13.2%) 61,948 (20.9%) 79,753 (29.7%)
Folic acid 26,219 (7.1%) 31,637 (10.7%) 47,546 (17.7%)
Homocysteine 1708 (0.5%) 2530 (0.9%) 2427 (0.9%)
Methylmalonic acid 175 (0.0%) 196 (0.1%) 237 (0.1%)
Holotranscobalamin 18,360 (5.0%) 23,363 (7.9%) 33,171 (12.4%)
Vitamin B12 41,880 (11.3%) 50,922 (17.2%) 71,863 (26.8%)
Other vitamins 3967 (1.1%) 4210 (1.4%) 2722 (1.0%)
Minerals (all) 34,343 (9.3%) 49,280 (16.6%) 69,770 (26.0%)
Magnesium 10,055 (2.7%) 13,086 (4.4%) 15,178 (5.7%)
Calcium 32,439 (8.8%) 47,289 (16.0%) 67,681 (25.2%)
Trace elements (all) 82,007 (22.1%) 76,712 (25.9%) 92,653 (34.5%)
Iron 16,166 (4.4%) 17,647 (6.0%) 20,146 (7.5%)
Ferritin 81,316 (22.0%) 75,753 (25.6%) 91,551 (34.1%)
Transferrin 9434 (2.5%) 10,589 (3.6%) 12,673 (4.7%)
Other trace elements 6074 (1.6%) 5845 (2.0%) 3567 (1.3%)
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The incidence we calculated disregarded multiple 
annual tests in individual patients. Therefore, we investi-
gated the frequency of specific tests per person. The MLT 
with the highest rate of being performed multiple times in 
individual persons was ferritin. Given the need for monitor-
ing iron levels in patients requiring iron supplementation, 
a comparably high testing frequency seems understandable. 
However, the observation that more than seven percent of 
the entire Swiss population still received two or more ferri-
tin tests in 2018 argues for a very high testing frequency 
which is possibly related to the easy access and reimburse-
ment of advanced iron supplementation treatments in 
Switzerland.25,26 Vitamin D was in second place and vita-
min B12 third place of MLT performed with high fre-
quency, being tested twice or more in 4% and 3% of the 
Swiss population respectively in 2018. Repeated testing of 
these vitamins within one year is rather inexplicable since 
once detected, these vitamin deficiencies can usually be 
safely treated without the need for re-assessment. 
Therefore, these repeated MLT tests are especially suspect 
for potential overtesting. Calcium tests were performed 
twice or more in 4% of the population but since calcium 
requires closer monitoring in some patients (depending on 
comorbidities and medications) these repeat tests may be 
clinically appropriate in many cases.
Strengths and Limitations
The main strengths of this study are: First, the population- 
based approach including more than six million person years 
and almost one million persons in 2018 (more than 10% of 
the entire population). Second, the completeness of the data 
(covering all healthcare invoices from inpatient and outpa-
tient setting). Third, the representativeness of the 
database.12,13 Fourth, the comprehensiveness focusing on 
a large set of MLT rather than a single laboratory test. 
Limitation of the study includes the potential for under- 
reporting of claims (approximately 3% according to internal 
Helsana analyses are underreported and are paid out-of- 
pocket). Thus, there is a potential underestimation of MLT 
in our data and actual MLT may be even more frequent than 
estimated by our study. However, our study still represents 
MLT payed for within the insurance system and thereby the 
part that is of greatest public concern. Second, since our data 
did not include clinical parameters (laboratory values) and 
diagnoses (eg for osteoporosis or anemia) we were unable to 
determine the actual appropriateness of MLT.
Implications for Research
The very high frequency of MLT and the strong temporal 
trends strongly indicate a need for further investigations 
since such potentially inappropriate testing may be respon-
sible for substantial avoidable expenditures. Future 
research should therefore first precisely identify inap-
propriate use of MLT, and secondly targeted interventions 
should be tested to reduce inappropriate use of MLT. 
Among such possible interventions are campaigns such 
as “choosing wisely” or “smarter medicine” that focus on 
recommendations on interventions to avoid.9,27
Table 5 Frequency of MLT in 2018
Test Number of Tests
0 1 2 ≥3
N (%) N (%) N (%) N (%)
Ferritin 686,065 (73.4%) 180,923 (19.4%) 46,332 (5.0%) 21,365 (2.3%)
Vitamin D 744,097 (79.6%) 148,388 (15.9%) 32,119 (3.4%) 10,081 (1.1%)
Vitamin B12 770,020 (82.4%) 133,386 (14.3%) 24,667 (2.6%) 6612 (0.7%)
Calcium 787,276 (84.2%) 106,131 (11.4%) 23,694 (2.5%) 17,584 (1.9%)
Folic acid 829,283 (88.7%) 87,727 (9.4%) 13,924 (1.5%) 3751 (0.4%)
Holotranscobalamin 859,791 (92.0%) 64,512 (6.9%) 85 23 (0.9%) 1859 (0.2%)
Iron 880,726 (94.2%) 42,935 (4.6%) 7977 (0.9%) 3047 (0.3%)
Magnesium 896,366 (95.9%) 30,183 (3.2%) 4982 (0.5%) 3154 (0.3%)
Transferrin 901,989 (96.5%) 26,029 (2.8%) 4801 (0.5%) 1866 (0.2%)
Other trace elements 919,199 (98.3%) 9789 (1.0%) 4 097 (0.4%) 1600 (0.2%)
Other vitamins 923,786 (98.8%) 4285 (0.5%) 2726 (0.3%) 3888 (0.4%)
Homocysteine 928,020 (99.3%) 5799 (0.6%) 697 (0.1%) 169 (0.0%)
Methylmalonic acid 934,077 (99.9%) 597 (0.1%) 11 (0.0%) 0 (0.0%)
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Implications for Practice
For physicians, the results of our study suggest the need 
for reflecting current use of MLT and possibly reducing 
unnecessary tests. Guideline authors and opinion leaders 
could bring up the topic amongst physicians and public 
campaigns could inform the general population about the 
actual value and limitations of MLT.
Conclusion
In conclusion, the present study shows a high incidence 
and a strong increase in MLT in Switzerland and raises 
concerns about potential inappropriateness.
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